We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
胶体果胶铋胶囊联合维酶素片对慢性萎缩性胃炎患者 血清胃蛋白酶原和炎症因子的影响.
- Authors
夏冬丽; 沈文拥; 魏沙; 易志强; 刘爱民
- Abstract
To observe the effects of colloidal pectin bismuth capsule combined with vitacoenzyme tablets on serum pepsinogen and inflammatory factors in patients with chronic atrophic gastritis (CAG). 98 patients with CAG who were treated in Fuling Hospital Affiliated to Chongqing University from April 2019 to March 2021 were selected. According to the two-color ball method, the patients were divided into control group (n=49) and experimental group (n=49). The patients in the control group and the experimental group received vitacoenzyme tablets, colloidal pectin bismuth capsule combined with vitacoenzyme tablets, both groups were treated for 4 weeks. The curative effects and the changes of serum pepsinogen I (PGⅠ), pepsinogen Ⅱ (PGⅡ), gastrin-17 (G-17), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), soluble interleukin-2 receptor (sIL-2R) and tumor necrosis factor-α (TNF-α) in the two groups were observed. The drug safety of the two groups was recorded. After treatment, the total clinical effective rate of the control group was 71.43%, which was lower than 93.88% of the experimental group (P<0.05). After treatment, PG Ⅱ in the two groups decreased compared with that before treatment, PG Ⅰ and G-17 increased compared with those before treatment (P<0.05), and the changes of PGⅠ, PGⅡ and G-17 in the experimental group were more obvious (P<0.05). After treatment, the inflammatory factor indexes of IL-6, hs-CRP, sIL-2R and TNF-α in the two groups were decreased compared with those before treatment (P<0.05), and the changes of inflammatory factors in the experimental group were more obvious (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Colloidal pectin bismuth capsule combined with vitacoenzyme tablet in the treatment of patients with CAG has a significant therapeutic effect, can effectively regulate the level of gastric mucosa related and inflammatory factors, and does not increase the incidence of adverse reactions, and has a good clinical application value.
- Subjects
ATROPHIC gastritis; GASTRIC mucosa; C-reactive protein; PEPSINOGEN; EXPERIMENTAL groups
- Publication
Progress in Modern Biomedicine, 2021, Vol 21, Issue 23, p4541
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2021.23.030